(Q54141444)

English

High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

colorectal cancer

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

Sharyn D. Baker

2

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

author name string

E K Rowinsky

1

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

K Burks

3

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

S O'Reilly

4

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

R C Donehower

5

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

L B Grochow

6

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

publication date

1 February 1998

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

9

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

2

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

173-180

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

The current status of camptothecin analogues as antitumor agents

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan, an active new antineoplastic agent: review and current status

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Intrathecal administration of topotecan in nonhuman primates

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008266630701

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008266630701

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9553662

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54141444&oldid=2144196983"